Aptar Pharma, a global leader in drug delivery systems, services and active packaging solutions, announced that its patented Unidose Liquid System is the device delivering a new nasal spray approved by the U.S. FDA for another rescue treatment for people with epilepsy aged six and older suffering from acute repetitive seizures. This ready-to-use rescue treatment can be used when and where a seizure cluster occurs thanks to Aptar’s proven, intuitive and convenient Unidose Liquid System.
This approval again demonstrates Aptar’s expertise in developing patient-friendly drug delivery solutions to help pharmaceutical customers address unmet healthcare needs. Aptar offers a broad portfolio of innovative technologies and wide array of services to meet the highest quality standards of the pharmaceutical industry.
This new rescue treatment for seizure activity is an example of a Combination Product submission, and benefited from Aptar Pharma’s services offering, a comprehensive portfolio of stage-specific development packages.
“The launch of our Unidose System for this new U.S. FDA-approved nasal rescue treatment for seizure activity once again demonstrates Aptar Pharma’s ability to help our customers develop and launch complex treatments,” stated Gael Touya, President, Aptar Pharma. “Our proven nasal systems combined with our lab and analytical service capabilities create substantial value for our customers and help them secure approval. The ultimate end result is that we help expand life-saving treatments with our patient-friendly systems.”
